Physician profile
William B Harper
NPI 1578657409
$1,851.79
in general payments reported to CMS, 2019-2025
23 companies · $792 in 2025
The $792 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.52 · 2021: $17.09 · 2022: $232 · 2023: $228 · 2024: $565 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,585.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $280.81 | 2022-2025 | |
| Novo Nordisk INC | $226.82 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $172.71 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $159.09 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $121.03 | 2024-2025 | |
| Amgen INC. | $114.78 | 2024-2025 | Evenity, Otezla, Repatha |
| Coloplast Corp | $110.77 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $85.94 | 2024-2025 | Breztri, Airsupra |
| Abbott Laboratories | $83.32 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $64.63 | 2023-2024 | Veozah |
| Medtronic, INC. | $52.52 | 2022-2024 | Interstim |
| Dexcom, INC. | $51.45 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $43.70 | 2023-2025 | Lagevrio, Belsomra |
| Pfizer INC. | $42.67 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.27 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $36.89 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.12 | 2025 | Jardiance |
| Abbvie INC. | $30.65 | 2021-2023 | |
| Inspire Medical Systems, INC. | $23.13 | 2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $23.07 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.72 | 2024 | Xifaxan |
| Becton, Dickinson and Company | $17.08 | 2024 | Venclose Maven Catheter |
| Sumitomo Pharma America, INC. | $16.62 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.